PopularGilead ordered to pay Merck US$200m for hepatitis C patentsBy localnewsingapore@gmail.com - March 27, 20160256 Share on Facebook Tweet on Twitter GILEAD Sciences Inc was ordered by a jury to pay Merck & Co US$200 million for patent infringement over a drug compound that cures hepatitis C, a tenth of what Merck sought. Source link Related
